Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy

NCT04489173 is registered in ClinicalTrials.gov with Borstkanker Onderzoek Groep as lead sponsor.

NCT NCT04489173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04489173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy
Lead sponsor
Borstkanker Onderzoek Groep
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2020
Completion date
May 19, 2026
Enrollment
52 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm, chemotherapy effect